Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Quick Links Corporate Presentation Responsibility News Portfolio Responsibility Report Annual Reports Leadership Governance SEC Filings Latest Press Releases December 5, 2022 Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology December 2, 2022 Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia November 17, 2022 Incyte to Present at Upcoming Investor Conferences All press releases Latest Events Dec 11 2022 Dec 11 2022 Incyte LIMBER Data Highlights from ASH 2022 Click here for Webcast Dec 7 2022 Dec 7 2022 Bank of America Securities Biotech SMID Cap Conference Click here for Webcast All events
